July 1, 2022
LexaGene is pleased sell a MiQLab System into a veterinary hospital in Wisconsin.
June 30, 2022
LexaGene was granted a management cease trade order while it prepares its year-end financial statements for Canada.
LexaGene Files Form 10 Registration Statement with the SEC and Announces a Delay in Filing Year-End Annual Canadian Financial Filings
June 28, 2022
LexaGene has filed an initial registration statement with the United States Securities and Exchange Commission (the “SEC”) on Form 10 under the United States Securities Exchange Act of 1934.
May 25, 2022
LexaGene is pleased to announce a large veterinary animal health corporation has purchased two MiQLab® Systems for two of their locations.
May 3, 2022
The U.S. Army Combat Capabilities Development Command Chemical Biological Center (DEVCOM Chemical Biological Center) has successfully completed the evaluation of the MiQLab System for biothreat detection.
April 25, 2022
LexaGene is pleased to announce a corporate veterinary reference laboratory has purchased 3 MiQLab® Systems for one of their many locations.
March 29, 2022
To better handle more complex samples, we have recently embedded a new chemistry into our sample preparation cartridge that greatly improves the MiQLab System’s ability to process samples that contain a significant percentage of blood, which is a powerful inhibitor of PCR.
February 23, 2022
The second tranche of the previously announced private placement to Meridian LGH Holdings, LLC has closed.
February 8, 2022
Meridian LGH Holdings LLC, (the “Investor”) has agreed to make an investment in LexaGene for a total of CAD$6,475,000 (approximately USD$4,995,000). The Company and the Investor intend that the investment will occur by way of non-brokered private placement (the “Private Placement”) anticipated to close in two tranches.
January 3, 2022
Today, LexaGene announced purchase orders for MiQLab™ Systems from veterinary clinics in Michigan, Minnesota, and New York.
For Marketing inquiries, please email: